Healthcare
Live Price
Offline$166.40
+11.60% today
Window Change
+16.31%
Window
May 29, 2026 → Jun 22, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 29, 2026 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nutex Health, Inc. (NUTX) is a Healthcare stock with a market cap of $830.00M and listed on NASDAQ. The stock last traded around $166.40 and up 16.3% across the available one-year price window (May 29, 2026 → Jun 22, 2026). Baseline metrics include revenue growth of +82.4%, EPS growth of +8.8%, a dividend yield of 0.0%. What stands out right now is revenue +82.4%, EPS +8.8%, free cash flow +1077.9% with operating margin 31.4% and ROIC 26.6%. Valuation is more restrained than many high-expectation growth names at P/E 9.7 and price/sales 0.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines NUTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
NUTX is 17.91 pts ahead over the shared 1Y window.
NUTX had 5.97 pts shallower max drawdown than SPY.
NUTX beat SPY in 1 of 1 calendar years shown and trailed in 0.
NUTX
+16.31%
Normalized return
SPY
-1.60%
S&P 500
Excess Return
+17.91 pts
Relative to SPY
NUTX Max Drawdown
-3.16%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for NUTX and SPY.
| Year | NUTX | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | +16.31% | +6.71% | +9.60 pts | NUTX |
| 2025 | — | +11.19% | -- | -- |
Unable to load analyst forecasts.
Timed out loading forecasts for NUTX
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.